A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: A case-control study

被引:189
作者
Valkenburg, Olivier [1 ]
Steegers-Theunissen, Regine P. M. [2 ,3 ,4 ,5 ]
Smedts, Huberdina P. M. [2 ]
Dallinga-Thie, Geesje M. [6 ]
Fauser, Bart C. J. M. [7 ]
Westerveld, Egbertine H. [8 ]
Laven, Joop S. E. [1 ]
机构
[1] Erasmus MC, Div Reprod Med, Dept Gynecol & Obstet, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Div Obstet & Prenatal Med, NL-3000 CA Rotterdam, Netherlands
[3] Erasmus MC, Dept Epidemiol & Biostat, Dept Gynecol & Obstet, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Div Reprod Med, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands
[5] Erasmus MC, Dept Pediat, Div Pediat Cardiol, NL-3000 CA Rotterdam, Netherlands
[6] Acad Med Ctr, Lab Expt Vasc Med, NL-1100 DD Amsterdam, Netherlands
[7] Univ Med Ctr, Dept Reprod Med, NL-3508 GA Utrecht, Netherlands
[8] Univ Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
关键词
D O I
10.1210/jc.2007-1756
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Context: Polycystic ovary syndrome (PCOS) is associated with a higher frequency of cardiovascular risk factors. Apolipoprotein (apo) A-I and apoB are potent markers for cardiovascular risk. Data on apo levels in women with PCOS are scarce and contradictory. Objective: Our objective was to identify changes in lipid metabolism in women with PCOS, and the relative impact of obesity, insulin resistance, and hyperandrogenism on lipid parameters. Design: This was a case-control study. Setting: The study was performed at a single referral center. Subjects: PCOS was diagnosed according to the 2003 Rotterdam criteria. Healthy mothers with regular menstrual cycles served as controls. Main Outcome Parameters: Fasting insulin, triglycerides (TGs), cholesterol, high-density lipoprotein (HDL)-cholesterol, apoA-I, and apoB were determined. Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald formula. Results: We included 557 women with PCOS and 295 controls. After correction for age and body mass index, PCOS women had higher median levels of insulin (10.1 vs. 6.9 mU/liter), TGs (95 vs. 81 mg/dl), cholesterol (196 vs. 178 mg/dl), and LDL-cholesterol (125 vs. 106 mg/dl) in combination with lower levels of HDL-cholesterol (46 vs. 55 mg/dl) and apoA-I (118 vs. 146 mg/dl) compared with controls (all P values <= 0.01). apoB levels were similar in cases and controls. Free androgen index, body mass index, SHBG, and estradiol were independent predictors of apoA-I levels in women with PCOS. Conclusions: PCOS is associated with a more pronounced atherogenic lipid profile. Furthermore, obesity and hyperandrogenism contribute to an adverse lipid profile. Finally, PCOS seems to constitute an additional risk factor for an atherogenic lipid profile.
引用
收藏
页码:470 / 476
页数:7
相关论文
共 35 条
[1]
The rationale for using apoA-I as a clinical marker of cardiovascular risk [J].
Barter, PJ ;
Rye, KA .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) :447-454
[2]
Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis [J].
Barter, PJ ;
Brewer, HB ;
Chapman, MJ ;
Hennekens, CH ;
Rader, DJ ;
Tall, AR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :160-167
[3]
Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) [J].
Bickerton, AST ;
Clark, N ;
Meeking, D ;
Shaw, KM ;
Crook, M ;
Lumb, P ;
Turner, C ;
Cummings, MH .
JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (02) :151-154
[4]
BRUNZELL JD, 2003, AM J MED S 8A, V114, pS24
[5]
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[6]
Smaller LDL particle size in women with polycystic ovary syndrome compared to controls [J].
Dejager, S ;
Pichard, C ;
Giral, P ;
Bruckert, E ;
Federspield, MC ;
Beucler, I ;
Turpin, G .
CLINICAL ENDOCRINOLOGY, 2001, 54 (04) :455-462
[7]
Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Liljenquist, DR ;
Kasza, K ;
Azziz, R ;
Legro, RS ;
Ghazzi, MN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :48-53
[8]
Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects [J].
Elbers, JMH ;
Giltay, EJ ;
Teerlink, T ;
Scheffer, PG ;
Asscheman, H ;
Seidell, JC ;
Gooren, LJG .
CLINICAL ENDOCRINOLOGY, 2003, 58 (05) :562-571
[9]
STUDIES ON THE METABOLIC MECHANISM OF REDUCED HIGH-DENSITY LIPOPROTEINS DURING ANABOLIC-STEROID THERAPY [J].
HAFFNER, SM ;
KUSHWAHA, RS ;
FOSTER, DM ;
APPLEBAUMBOWDEN, D ;
HAZZARD, WR .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (04) :413-420
[10]
PRELIMINARY-REPORT - KINETIC-STUDIES ON THE MODULATION OF HIGH-DENSITY LIPOPROTEIN, APOLIPOPROTEIN, AND SUBFRACTION METABOLISM BY SEX STEROIDS IN A POSTMENOPAUSAL WOMAN [J].
HAZZARD, WR ;
HAFFNER, SM ;
KUSHWAHA, RS ;
APPLEBAUMBOWDEN, D ;
FOSTER, DM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (09) :779-784